Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure

Journal of Medical Virology

Volumn 79, Issue 7, 2007, Pages 865-872

  Lwembe, Raphael ^a,b   Ochieng, Washingtone ^a   Panikulam, Annie ^c   Mongoina, Charles O ^c   Palakudy, Tresa ^c   Koizumi, Yusuke ^b   Kageyama, Seiji ^b   Yamamoto, Naohiko ^d   Shioda, Tatsuo ^e   Musoke, Rachel ^c   Owens, Mary ^c   Songok, Elijah M ^a   Okoth, Frederick A ^a   Ichimura, Hiroshi ^b  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b KANAZAWA UNIVERSITY   (Japan)

^c Nyumbani Children's Home   (Kenya)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

Anti HIV resistance patterns; Kenya; Persistence of mutations; Vertical transmission

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CHILD; CLONE; DRUG TREATMENT FAILURE; FEMALE; GENE AMPLIFICATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; KENYA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHYLOGENY; POL RT GENE; PROGNOSIS; VERTICAL TRANSMISSION; VIRUS GENE; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

ANTI-HIV AGENTS; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KENYA; MALE; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT FAILURE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34249907870     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20912     Document Type: Article

References (45)

1. Apetrei C, Descamps D, Collin G, Loussert-Ajaka I, Damond F, Duca M, Simon F, Brun-Vezinet F. 1998. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. J Virol 72:3534-3538.
2. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, Tsay J, Ip J, Farthing C, Limoli K, Parkin N, Markowitz M. 1999. HIV-1 drug resistance in newly infected individuals. JAMA 282:1135-1141.
3. Brenner B, Wainberg MA, Salomon H, Rouleau D, Dascal A, Spira B, Sekaly RP, Conway B, Routy JP. 2000. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study. Int J Antimicrob Agents 16:429-434.
4. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R, Sekaly RP, Wainberg MA. 2002. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 76:1753-1761.
5. Charpentier C, Dwyer DE, Mammano F, Lecossier D, Clavel F, Hance AJ. 2004. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol 78:4234-4247.
6. Coffin JM. 1995. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
7. Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. 1994. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis 169: 411-415.
8. Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P, Ledergerber B, Holkmann C, Staszewski S, Lundgren JD, Euro-SIDA Study Group. 2005. Thymidine analogue mutation profiles: Factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 10: 791-802.
9. D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, Richman DD. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Int Med 122:401-408.
10. de Ronde A, van Dooren M, van Der Hoek L, Bouwhuis D, de Rooij E, van Gemen B, de Boer R, Goudsmit J. 2001. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol 75:595-602.
11. Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, Walter H, Pauli G, Kucherer C. 2001. Frequency of genotypic and phenotypic
12. drug-resistant HTV-1 among therapy-naïve patients of the German Seroconverter Study. J Acquir Immune Defici Syndr 26:266-273.
13. Dykes C, Fox K, Lloyd A, Chiulli M, Morse E, Demeter LM. 2001. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology 285:193-203.
14. Dykes C, Najjar J, Bosch RJ, Wantman M, Furtado M, Hart S, Hammer SM, Demeter LM. 2004. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. J Infect Dis 189:1091-1096.
15. Edelstein RE, Nickerson DA, Tobe VO, Manns-Arcuino LA, Frenkel LM. 1998. Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J Clin Microbiol 36:569-572.
16. Erice A, Mayers DL, Strike DG, Sannerud KJ, McCutchan FE, Henry K, Balfour HH Jr. 1993. Brief report: Primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 328:1163-1165.
17. Flandre P, Descamps D, Joly V, Meiffredy V, Tamalet C, Izopet J, Aboulker JP, Brun-Vezinet F. 2003. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received. Antivir Ther 8:65-72.
18. Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, Musoke P, Mmiro F, Strathern JN, Jackson JB, Eshleman JR, Eshleman SH. 2005. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 192:24-29.
19. Garcia-Lerma JG. 2005. Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons. J Antimicrob Chemother 56:265-269.
20. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO. 2002. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288:181-188.
21. Gunthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD. 1998. Comparative performance of high-density oligonucleotide and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses 14:869-876.
22. Johnson VA, Petropoulos CJ, Woods CR, Hazelwood JD, Parkin NT, Hamilton CD, Fiscus SA. 2001. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HTV-1-infected infant. J Infect Dis 183:1688-1693.
23. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD. 2005. Update of the drug resistance mutations in HIV-1:2005. Top HIV Med 13:51-57.
24. Johnson JA, Li J-F, Wei X, Craig C, Stone C, Horton JH, Lanier ER, Heneine W. 2006. Baseline detection of low-frequency drug resistance-associated mutations is strongly associated with virological failure in previously antiretroviral naïve HIV-infected persons. Anti Therapy 11:S79.
25. Kline MW, Fletcher CV, Federici ME, Harris AT, Evans KD, Rutkiewicz VL, Shearer WT, Dunkle LM. 1996. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: Pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics 97:886-890.
26. Lecossier D, Shulman NS, Morand-Joubert L, Shafer RW, Joly V, Zolopa AR, Clavel F, Hance AJ. 2005. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 38:37-42.
27. Little SJ, Daar ES, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, Hellmann NS, Petropoulos CJ, Sutton L, Pitt JA, Rosenberg ES, Koup RA, Walker BD, Richman DD. 1999. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282:1142-1149.
28. Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, Perneger TV, Perrin L, Kaiser L, Yerly S. 1999. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 13:F17-. F21.
29. Malet I, Belnard M, Agut H, Cahour A. 2003. From RNA to quasispecies: A DNA polymerase with proofreading activity is highly recommended for accurate assessment of viral diversity. J Virol Methods 109:161-170.
30. Metzner KJ, Bonhoeffer S, Fischer M, Karanicolas R, Allers K, Joos B, Weber R, Hirschel B, Kostrikis LG, Gunthard HF, The Swiss HIV Cohort Study. 2003. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 188:1433-1443.
31. NASCOP. 2002. National Guidelines: Prevention of mother to child HIV/AIDS transmission 2nd edition.
32. Ndembi N, Takehisa J, Zekeng L, Kobayashi E, Ngansop C, Songok EM, Kageyama S, Takemura T, Ido E, Hayami M, Kaptue L, Ichimura H. 2004. Genetic diversity of HIV type 1 in rural eastern Cameroon. J Acquir Immune Defic Syndr 37:1641-1650.
33. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, Rock D, Falloon J, Davey RT Jr, Dewar RL, Metcalf JA, Hammer S, Mellors JW, Coffin JM. 2005. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 43:406-413.
34. Pieniazek D, Rayfield M, Hu DJ, Nkengasong J, Wiktor SZ, Downing R, Biryahwaho B, Mastro T, Tanuri A, Soriano V, Lal R, Dondero T. 2000. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naïve individuals worldwide. HIV Variant Working Group. AIDS 14:1489-1495.
35. Pillay D, Cane PA, Shirley J, Porter K. 2000. Detection of drug resistance associated mutations in HIV primary infection within the UK. AIDS 14:906-908.
36. Quinones-Mateu ME, Albright JL, Mas A, Soriano V, Arts EJ. 1998. Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1. J Virol 72:9002-9015.
37. Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, Starr S, Spector SA. 2005. An MDR1-3435variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 19:371-380.
38. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, LeBlane R, Lefebvre E, Spira B, Tsoukas C, Sekaly RP, Conway B, Mayers D, Routy JP. 2000. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 14:F17-F23.
39. Schuurman R, Brambilla D, de Groot T, Huang D, Land S, Bremer J, Benders I, Boucher CA, ENVA Working Group. 2002. Underestimation of HIV type 1 drug resistance mutations: Results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses 18:243-248.
40. Shi C, Eshleman SH, Jones D, Fukushima N, Hua L, Parker AR, Yeo CJ, Hruban RH, Goggins MG, Eshleman JR. 2004. LigAmp for sensitive detection of single-nucleotide differences. Nat Methods 1:141-147.
41. Songok EM, Lwembe RM, Kibaya R, Kobayashi K, Ndembi N, Kita K, Vulule J, Oishi I, Okoth F, Kageyama S, Ichimura H. 2004. Active generation and selection for HIV intersubtype A/D recombinant forms in a coinfected patient in Kenya. AIDS Res Hum Retroviruses 20:255-258.
42. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, Oka S. 2004. Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319:1322-1326.
43. Weinberg MA. 2003. HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 34:S2-S7.
44. Yerly S, Rakik A, De Loes SK, Hirschel B, Descamps D, Brun-Vezinet F, Perrin L. 1998. Switch to unusual amino acids at codon 215 of human immunodeficiency virus type 1 reverse transcriptase gene in seroconverters infected with zidovudine-resistant variants. J Virol 72:3520-3523.
45. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC, Efron B. 1999. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 131:813-821.